Tixagevimab/cilgavimab for the prevention of COVID-19 in solid organ transplant recipients
Description
Tixagevimab/cilgavimab (tix/cil) received emergency use authorization in December 2021 for pre-exposure prophylaxis against COVID-19 in moderately to severely immunocompromised patients. Our study aimed to describe the incidence of COVID-19 infection
